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Background: We investigated whether polymorphisms in the toll-like receptor genes or gene–gene interactions
are associated with susceptibility to latent tuberculosis infection (LTBI) or subsequent pulmonary tuberculosis (PTB)
in a Chinese population.
Methods: Two matched case–control studies were undertaken. Previously reported polymorphisms in the toll-like
receptors (TLRs) were compared between 422 healthy controls (HC) and 205 LTBI patients and between 205 LTBI
patients and 109 PTB patients, to assess whether these polymorphisms and their interactions are associated with
LTBI or PTB. A PCR-based restriction fragment length polymorphism analysis was used to detect genetic
polymorphisms in the TLR genes. Nonparametric multifactor dimensionality reduction (MDR) was used to analyze
the effects of interactions between complex disease genes and other genes or environmental factors.
Results: Sixteen markers in TLR1, TLR2, TLR4, TLR6, TLR8, TLR9, and TIRAP were detected. In TLR2, the frequencies of the
CC genotype (OR = 2.262; 95% CI: 1.433–3.570) and C allele (OR = 1.566; 95% CI: 1.223–1.900) in
single-nucleotide polymorphism (SNP) rs3804100 were significantly higher in the LTBI group than in the HC group,
whereas the GA genotype of SNP rs5743708 was associated with PTB (OR = 6.087; 95% CI: 1.687–21.968). The
frequencies of the GG genotype of SNP rs7873784 in TLR4 (OR = 2.136; 95% CI: 1.312–3.478) and the CC genotype of
rs3764879 in TLR8 (OR = 1.982; 95% CI: 1.292-3.042) were also significantly higher in the PTB group than in the HC group.
The TC genotype frequency of SNP rs5743836 in TLR9 was significantly higher in the LTBI group than in the HC group
(OR = 1.664; 95% CI: 1.201–2.306). An MDR analysis of gene–gene and gene–environment interactions identified three
SNPs (rs10759932, rs7873784, and rs10759931) that predicted LTBI with 84% accuracy (p= 0.0004) and three SNPs
(rs3804100, rs1898830, and rs10759931) that predicted PTB with 80% accuracy (p = 0.0001).
Conclusions: Our results suggest that genetic variation in TLR2, 4, 8 and 9, implicating TLR-related pathways affecting
the innate immunity response, modulate LTBI and PTB susceptibility in Chinese.
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Mycobacterial infections remain a leading global health
threat and are of major concern worldwide. The World
Health Organization estimates that about one third of
the world’s population is infected with Mycobacterium
tuberculosis (Mtb), and that about 1.4 million deaths* Correspondence: bxu@shmu.edu.cn
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unless otherwise stated.from tuberculosis (TB) occur each year [1]. Approxi-
mately 10% of individuals infected with Mtb develop ac-
tive pulmonary disease, suggesting that there are
differences in the susceptibility or resistance to disease
development among individuals [2]. The results of twin
[3] and family-based studies [4] support the role of gen-
etics in the development of pulmonary TB (PTB).
Furthermore, both human and mouse studies of myco-
bacterial infections have identified several potential
TB-susceptibility or -resistance loci, including genes in-
volved in toll-like receptor (TLR) signaling [5].is is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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the innate immune system as a first-line host defense
mechanism. In humans, the TLRs contribute to this in-
nate immune recognition of pathogens and shape the
development of the adaptive immune response [5]. Mtb
is initially recognized by TLR1, TLR2, TLR4, and TLR6,
which then interact with the adaptor proteins MyD88
and toll-interleukin 1 receptor (TIR) domain containing
adaptor protein (TIRAP) to activate macrophages and
dendritic cells [6,7]. TLRs play an integral role in the ac-
tivation of the inflammatory cytokine signaling pathways
and the adaptive immune response and as a result, have
become biologically plausible candidate genes in studies
of TB susceptibility [8]. Human genetic studies have also
indicated that variants of the TLR pathway genes, in-
cluding TLR1 [9], TLR2 [10,11], TLR4 [12], and TIRAP
[13], regulate the cellular immune response and may in-
fluence human susceptibility to Mtb in different popula-
tions [14]. However, these findings have not been
replicated in different populations [15], and this lack
of information has hindered the discovery of genetic
susceptibility factors for this disease. Therefore, it is
essential that we investigate whether polymorphic var-
iants of the TLRs are associated with susceptibility to
TB in different populations, especially in areas with a
high TB burden.
In China, as in the rest of the world, TB is a significant
public health problem. In Shanghai, TB has a prevalence
of about 7,000 newly reported cases each year [16]. In a
previous study, we reported that more than 30% of latent
tuberculosis infections (LTBIs) cannot be explained by
socio-demographic or clinical factors, which suggests a
role for genetic factors [17]. The identification of high-
risk individuals among recently exposed/infected individ-
uals is extremely important in TB control programs
established to reduce the disease burden in communities.
There is strong functional evidence of a genetic compo-
nent involving the TLRs in human susceptibility to TB.
Therefore, in the present study, we examined PTB
patients, LTBI subjects, and healthy controls (HC) from
the Han population in Shanghai to test the association be-
tween 16 single-nucleotide polymorphisms (SNPs) of
TLR1, TLR2, TLR4, TLR6, and TLR9 and TB, to determine
the possible association of these polymorphisms with
disease susceptibility. We also investigated whether po-
tential single- or multi-locus gene interactions or
gene–environment interactions can predict the suscep-
tibility to LTBI or PTB.
Methods
Subjects
The patients with PTB (n = 109), subjects with LTBI
(n = 225), and HCs (n = 422) were recruited in the
metropolitan area of Shanghai, one of the largest citiesin China. The incidence rate of TB in Shanghai in
2008 was 24.6 per 100,000 inhabitants, according to
the municipal Center for Disease Prevention and Con-
trol (CDC).
Between 2011 and 2012, a total of 109 PTB patients
were recruited from seven district CDCs, the facilities
responsible for TB case management, in Shanghai. The
patients included in this study were newly diagnosed
with TB from sputum smear examinations for acid-fast
bacilli and/or the culture of Mtb in the hospitals desig-
nated to treat TB in these districts. The exclusion cri-
teria for patients included a positive serological test for
human immunodeficiency virus (HIV) infection, organ
transplantation, primary immunodeficiency, cancer, and
treatment with immunosuppressive drugs, endocrine
disorders such as diabetes, autoimmune or chronic
renal disease, and pleural, miliary, or meningeal TB.
In total, 225 LTBI subjects and 422 healthy individuals
were matched to the PTB patients by age, sex, and resi-
dency in the same district, were used as the control sub-
jects in the present study. The individuals with LTBI
were identified from the contacts of the participating
PTB patients at the time of their diagnosis, and were de-
fined as individuals who had had prolonged, frequent, or
intense contact with a registered TB patient while he or
she was infectious. The infectious period was defined
based on the U.S. CDC guidelines [18]. The individuals
with LTBI were ≥ 18 years old, HIV-seronegative, and
had a positive TSPOT.TB result, with no evidence of ac-
tive tuberculosis. The HCs were required to have a nega-
tive TSPOT.TB result, with no evidence of active
tuberculosis. The specific criteria for the enrollment of
the controls were the absence of pulmonary lesions on
chest radiography and no history of TB disease. The ex-
clusion criteria for HCs were the presence of a product-
ive cough for more than 2 weeks, a previous history of
TB, age < 15 years, and the presence of any clinical TB
symptoms during the 2 years of clinical follow-up.
This study was approved by the Institutional Review
Board of Fudan School of Public Health, Shanghai, and
written informed consent was obtained from all the par-
ticipants before blood sampling and a questionnaire-
based interview.
Determination of sample size
The sample size and statistical power were calculated
with the PASS software (version 12.0; NCSS LLS, Kaysville,
UT), based on the following parameters: 80% power,
α = 0.05, a polymorphism prevalence of 10%, an allelic
odds ratio for TB/LTBI of 2 compared with the control,
and a match ratio of 2:1. Using these parameters and as-
sumptions, the minimum sample size for each group was
estimated to be 100 for the PTB group, 200 for the LTBI
group, and 400 for the HC group.
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At the time of recruitment, the contacts of the TB
patients were interviewed by trained community health
workers and immediately afterwards, a 5-ml blood sam-
ple was taken from each for the TSPOT.TB assay. Indi-
viduals with TB symptoms or with a positive TSPOT.TB
result were examined for TB disease with a radiological
examination. The contacts were asked for their sociode-
mographic and clinical information. Vaccination with
the bacillus Calmette–Guérin (BCG) vaccine was veri-
fied by the interviewer, who confirmed the presence of
BCG scars. All data were recorded on a standardized
questionnaire by the trained health workers in the
district CDCs.Blood samples and DNA isolation
We collected 5 ml of peripheral blood from each partici-
pant into a glass tube containing potassium ethylenedi-
aminetetraacetate. Genomic DNA was extracted with
the salting-out protocol, using ammonium acetate [19].
The optical density of the DNA was measured on a
Nanodrop spectrophotometer and 25–50 ng of DNA
was used for each PCR.Genotyping
A PCR-based restriction fragment length polymorphism
(PCR–RFLP) analysis was performed for TLR1 (SNP
rs5743618), TLR2 (rs3804099, rs5743708, rs3804100, and
rs1898830), TLR4 (rs4986790, rs4986791, rs11536889,
rs10759932, rs7873784, and rs10759931), TLR6
(rs5743810), TLR8 (129) (rs3764879), TLR9 (rs5743836
and rs1870884), and TIRAP (rs8177374) using genomic
DNA isolated from peripheral blood leucocytes. The for-
ward (F) and reverse (R) primer sequences (Sungon,
Shanghai, China) (Additional file 1: Table S1), and re-
striction enzymes (New England Biolabs, Inc., Ipswich,
MA) were used to detect the restriction digestion pat-
terns for the different alleles [13,20,21]. The PCRs were
performed under the appropriate cycling conditions:
initial denaturation at 95°C for 5 min, followed by
35 cycles of denaturation at 95°C for 30 s, annealing at
the appropriate temperature for 30s, and extension at
72°C for 30 s, with a final extension at 72°C for 2 min.
The annealing temperatures used were as follows:
TLR1_1805: rs5743618 55°C; TLR2: rs3804099 65°C,
rs5743708 65°C, rs3804100 63°C, and rs1898830 63°C;
TLR4: rs4986790 56°C, rs4986791 56°C, rs11536889
54°C, rs10759932 54°C, rs7873784 55°C, and rs10759931
54°C; TLR6: rs5743810 52°C; TLR8_129: rs3764879 57°C;
TLR9: rs5743836 59°C and rs1870884 60°C; and TIRAP:
rs8177374 62°C. The PCR products were digested with
the restriction endonucleases and the resulting frag-
ments were separated by electrophoresis at 100 V on 3%agarose gel containing 0.5 mg/ml ethidium bromide,
and visualized under UV light.Statistical analysis
The data were double entered on a spreadsheet
(Microsoft Excel) and any discrepancies were checked
with the original questionnaire data to ensure data
consistency. The clinical and demographic characteristics
were compared among the three groups (PTB, LTBI, and
HC) with ANOVA for continuous variables and with the
χ2 test or Fisher’s exact test for categorical variables. p <
0.05 was considered significant.
The allele and genotype frequencies of each poly-
morphism were determined by direct counting. The
genotype distributions for each polymorphism were
then tested for Hardy–Weinberg equilibrium values
with the χ2 test. The genotype and allele frequencies of
the different groups were compared by calculating the
odds ratios and 95% confidence intervals (CI) in a con-
ditional logistic regression model (STATA version 9.0;
College Station, TX). The linkage disequilibrium (LD)
coefficients D’ and r2 were then calculated for the
multi-locus polymorphisms studied in TLR2 and TLR4
to determine any co-segregation. The associations be-
tween the haplotypes and LTBI or TB were tested by
calculating the logistic regression (adjustments) statis-
tic and the corresponding p values and odds ratios (ORs)
with 95% confidence intervals (CIs) using the SNPStats
software (http://bioinfo.iconcologia.net/SNPstats/) [22].
The relationships between the TLR polymorphisms and
the risk of PTB or LTBI were evaluated with the non-
parametric MDR method [23]. Each best model was
tested for its accuracy, cross-validation consistency, and
significance level, determined with permutation testing,
testing accuracy, and testing OR (95% CI) in the MDR
analysis. Cross-validation consistency was defined as
the number of cross-validation replicates (partitions) in
which the same n-locus model was chosen as the best
model (i.e., the number of replicates in which the classi-
fication error was minimized). Bonferroni corrections
were applied to multiple comparisons. The level of sig-
nificant was p < 0.003125 (0.05/16).Results
Demographic data of the participants
The baseline characteristics of the study populations
are summarized in Table 1. The age and sex distribu-
tions were very similar in all three groups. There was a
significant difference between the PTB group and the
LTBI group in the proportion of participants who had
undergone BCG vaccination (87.2% versus 95.1%, re-
spectively; p = 0.01).
Table 1 Characteristics of the study participants
Characteristics TB (n = 109) No. (%) LTBI (n = 225) No. (%) HC (n = 422) No. (%) χ2/ANOVA TB.vs.LTBI χ2/ANOVA LTBI.vs.HC
Age, mean ± SD, (yrs) 45 ± 12.6 45 ± 16.5 45 ± 18.7 0.99 0.96
15~ 16(14.7) 34(15.1) 63(14.9) 1.00 1.00
30~ 27(24.8) 56(24.9) 105(24.9)
45~ 45(41.2) 92(40.9) 173(41.0))
60~ 21(19.3) 43(19.1) 81(19.2)
Male 74(67.9) 152(67.6) 285(67.5) 0.951 1.000
BCG vaccination 95(87.2) 214(95.1) 405(96.0) 0.01a 0.99
LTBI: latent tuberculosis infection; HC, health controls. SD, standard deviation.
ap < 0.05.
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The genotype frequency distributions for all 16 SNPs
investigated were consistent with Hardy–Weinberg
equilibrium in all three groups, except SNPs rs3804100
(p = 0.012) and rs5743836 (p = 0.023) in the LTBI
group, and rs7873784 in the LTBI (p = 0.0328) and PTB
(p = 0.0375) groups.
The genotype and allele distributions were first com-
pared between the HC and PTB groups. Compared with
the HC group, the PTB group had significantly higher
proportions of the GA genotype (p = 0.002; OR = 6.087;
95% CI: 1.687–21.968) and G allele (p = 0.002; OR =
5.943; 95% CI: 1.662–21.250) in rs5743708; the T allele
in rs4986791 (p = 0.002; OR = 1.910; 95% CI: 1.260–
2.896); the GG genotype in rs7873784 (p = 0.002; OR =
2.136; 95% CI: 1.312–3.478); the CC genotype in
TLR8_129 (p = 0.002; OR = 1.982; 95% CI: 1.292–3.042);
and the T allele in rs8177374 (p < 0.001; OR = 1.942;
95% CI: 1.238–3.048).
When we compared the genotype and allele distribu-
tions between the HC and LTBI groups, we found that
the following genotypes and alleles showed significant
associations with LTBI: rs3804100 (CC, p < 0.001; OR =
2.262; 95% CI = 1.433–3.570; C, p < 0.001; OR = 1.566;
95% CI = 1.233–1.990) and rs5743836 (TC, p = 0.002;
OR = 1.664; 95% CI = 1.201–2.306).
There were no significant differences in the geno-
type or allele frequencies between the PTB patients
and LTBI subjects. No other SNPs differed signifi-
cantly in their genotypes (Table 2) or allele frequencies
(Table 3) between the PTB patients, the LTBI subjects,
and the HCs.Haplotype analysis
Two haplotype block sets in TLR2 and TLR4 were
identified with the haplotype analysis (Table 4). We se-
lected four polymorphisms in TLR2 and eight polymor-
phisms in TLR4 after setting the threshold for the LD
coefficient (D’ > 0.80; Figure 1). The haplotype frequen-
cies of TLR4 were significantly higher in the PTBgroup than in the LTBI group, for rs10759931/
rs10759932 (AT, p < 0.001, OR = 2.00, 95% CI = 1.221–
3.289) and rs4986790/rs4986791 (AT, p < 0.001, OR =
3.59, 95% CI = 1.570–8.565). However, the frequencies
of the other haplotypes of TLR2 and TLR4 did not dif-
fer significantly among the three groups.Gene–gene and gene–environment interactions evaluated
with nonparametric MDR
After cross-validation and permutation tests of the gene–
gene and gene–environment interactions in relation to the
LTBI group, the best models included a one-marker model
(rs5743836) with 56% balanced accuracy and 9/10 cross-
validation consistency, a two-marker model (rs3804100,
rs1898830) with 69% balanced accuracy and 10/10 cross-
validation consistency, and a three-marker model (rs3804100,
rs1898830, rs10759931) with 80% balanced accuracy and
10/10 cross-validation consistency (Table 5). The inter-
action dendrogram also indicated a synergistic effect be-
tween rs3804100 and rs10759931.
Regarding the role of these interactions in predicting
PTB, we identified a one-marker model (BCG vaccin-
ation) that had maximum cross-validation consistency
and a maximum prediction accuracy of 61%, a two-
marker model (rs10759932, rs7873784) with 76% bal-
anced accuracy and a cross-validation consistency of
100% in predicting PTB risk (p = 0.0024 based on 1000-
fold permutation testing), and a three-marker model
(rs10759932, rs7873784, rs10759931) with 84% balanced
accuracy and a cross-validation consistency of 100%
(Table 5). The interaction dendrogram shows the
amount of information obtained about LTBI versus HC
using MDR, and indicates a synergistic effect between
rs10759932 and rs7873784.Discussion
Shanghai is a city with a moderate incidence of TB,
reaching 33.7 per 100,000 population in 1999 and 26.3
per 100,000 in 2000. Under these circumstances, all
children born in Shanghai are routinely vaccinated with
Table 2 Distributions of toll-like receptor genotypes in the three groups
dbSNPS Genotypes Frequencies (No., %) LTBI.vs.HC TB.vs.LTBI TB.vs.HC
HC (n = 422) LTBI (n = 225) TB (n = 109) p OR 95% CI p OR 95% CI p OR 95% CI
rs5743618 GG 2(0.5) 2(0.9) 1(0.9) 0.613 1.883 0.264-13.461 0.979 1.032 0.093-11.511 0.499 1.944 0.175-21.64
TG 70(16.6) 23(10.2) 10(9.2) 0.028 0.573 0.347-0.946 0.763 0.887 0.407-1.936 0.054 0.508 0.252-1.022
TT 350(82.9) 200(88.9) 98(89.9) 0.043 1.646 1.011-2.678 0.778 1.114 0.526-2.356 0.074 1.833 0.935-3.592
rs3804099 CC 51(12.1) 25(11.1) 9(8.3) 0.714 0.909 0.547-1.512 0.419 0.720 0.324-1.600 0.260 0.655 0.312-1.375
TC 180(42.6) 95(42.2) 36(33.0) 0.916 0.982 0.708-1.363 0.107 0.675 0.418-1.089 0.068 0.663 0.426-1.033
TT 191(45.3) 105(46.7) 64(58.7) 0.732 1.058 0.765-1.464 0.039 1.625 1.023-2.581 0.012 1.720 1.123-2.636
rs5743708 GA 4(0.9) 9(4.0) 6(5.5) 0.008 4.354 1.326-14.301 0.534 1.398 0.485-4.033 0.002 6.087 1.687-21.968a
GG 418(99.1) 216(96.0) 103(94.5) 0.008 0.229 0.051-0.836 0.534 0.715 0.221-2.513 0.002 0.164 0.046-0.593a
rs3804100 CC 42(10.0) 45(20.0) 21(19.2) <0.001 2.262 1.433-3.570a 0.875 0.955 0.536-1.700 0.007 2.159 1.218-3.829
TC 168(39.8) 90(40.0) 44(40.4) 0.963 1.008 0.724-1.402 0.949 1.015 0.637-1.619 0.916 1.023 0.666-1.572
TT 212(50.2) 90(40.0) 44(40.4) 0.013 0.660 0.476-0.917 0.949 0.985 0.618-1.570 0.066 0.671 0.437-1.028
rs1898830 AA 142(33.6) 68(30.2) 33(30.3) 0.375 0.854 0.602-1.211 0.992 1.003 0.609-1.649 0.504 0.856 0.543-1.351
AG 196(46.4) 113(50.2) 54(49.5) 0.360 1.163 0.842-1.608 0.907 0.973 0.616-1.538 0.564 1.132 0.743-1.725
GG 84(20.0) 44(19.6) 22(20.2) 0.915 0.978 0.651-1.469 0.893 1.040 0.587-1.843 0.948 1.018 0.602-1.720
rs4986790 AA 346(82.0) 181(80.4) 77(70.6) 0.630 0.904 0.598-1.365 0.045 0.585 0.345-0.991 0.009 0.529 0.327-0.855
AG 75(17.8) 42(18.7) 31(28.4) 0.778 1.062 0.699-1.613 0.043 1.732 1.094-3.050 0.013 1.839 1.132-2.987
GG 1(0.2) 2(0.9) 1(0.9) 0.245 3.776 0.341-41.869 0.979 1.032 0.093-11.51 0.369 3.898 0.242-62.825
rs4986791 CC 342(81.0) 179(79.6) 74(67.9) 0.649 0.910 0.607-1.365 0.020 0.543 0.324-0.911 0.003 0.495 0.309-0.791
CT 76(18.0) 43(19.1) 32(29.4) 0.730 1.076 0.710-1.629 0.035 1.759 1.036-2.987 0.009 1.892 1.169-3.061
TT 4(1.0) 3(1.3) 3(2.7) 0.699 1.412 0.313-6.365 0.396 2.094 0.416-10.551 0.141 2.958 0.652-13.415
rs11536889 CC 34(8.1) 17(7.6) 10(9.2) 0.822 0.933 0.509-1.701 0.611 1.236 0.546-2.798 0.706 1.153 0.551-2.413
GC 167(39.5) 86(38.2) 40(36.7) 0.737 0.945 0.678-1.317 0.787 0.937 0.584-1.504 0.583 0.885 0.573-1.368
GG 221(52.4) 122(54.2) 59(54.1) 0.653 1.077 0.779-1.490 0.987 0.996 0.630-1.577 0.743 1.073 0.703-1.637
rs10759932 CC 42(10.0) 21(9.3) 5(4.5) 0.800 0.931 0.537-1.616 0.129 0.467 0.171-1.274 0.079 0.435 0.168-1.127
TC 168(39.8) 90(40.0) 49(45.0) 0.963 1.008 0.724-1.402 0.389 1.225 0.772-1.945 0.330 1.235 0.807-1.888
TT 212(50.2) 114(50.7) 55(50.5) 0.917 1.017 0.736-1.406 0.972 0.992 0.628-1.567 0.967 1.009 0.662-1.537
rs7873784 CC 29(6.9) 19(8.4) 7(6.4) 0.467 1.250 0.684-2.283 0.518 0.744 0.303-1.827 0.868 0.930 0.396-2.184
GC 135(32.0) 57(25.4) 18(16.5) 0.078 0.721 0.501-1.037 0.070 0.583 0.324-1.050 0.001 0.421 0.244-0.726a
GG 258(61.1) 149(66.2) 84(77.1) 0.202 1.246 0.888-1.748 0.043 1.714 1.014-2.897 0.002 2.136 1.312-3.478a
rs10759931 AA 143(33.9) 90(40.0) 44(40.4) 0.123 1.301 0.931-1.817 0.949 1.015 0.637-1.619 0.207 1.321 0.857-2.035
AG 215(50.9) 113(50.2) 54(49.5) 0.860 0.971 0.703-1.343 0.907 0.973 0.616-1.538 0.793 0.945 0.620-1.440














Table 2 Distributions of toll-like receptor genotypes in the three groups (Continued)
rs5743810 CT 12(2.8) 8(3.6) 5(4.6) 0.618 1.260 0.507-3.128 0.648 1.304 0.416-4.084 0.357 1.643 0.566-4.766
TT 410(97.2) 217(96.4) 104(95.4) 0.618 0.790 0.293-2.276 0.648 0.773 0.215-3.057 0.357 0.609 0.210-1.766
TLR8_129 CC 133(31.5) 81(36.0) 52(47.7) 0.248 1.222 0.869-1.719 0.040 1.622 1.020-2.580 0.002 1.982 1.292-3.042a
CG 190(45.0) 96(42.7) 41(37.6) 0.565 0.909 0.656-1.259 0.379 0.810 0.507-1.295 0.164 0.736 0.478-1.134
GG 99(23.5) 48(21.3) 16(14.7) 0.539 0.885 0.599-1.307 0.147 0.634 0.342-1.178 0.047 0.561 0.315-0.999
rs5743836 CC 25(5.9) 13(5.8) 6(5.5) 0.940 0.974 0.488-1.943 0.919 0.950 0.351-2.571 0.868 0.925 0.370-2.314
TC 181(42.9) 125(55.5) 49(45.0) 0.002 1.664 1.201-2.306 0.069 0.653 0.412-1.035 0.698 1.087 0.712-1.661
TT 216(51.2) 87(38.7) 54(49.5) 0.002 0.601 0.433-0.836 0.059 1.557 0.982-2.471 0.760 0.936 0.614-1.427
rs1870884 CC 3(0.7) 1(0.4) 0(0) 1.000 0.624 0.064-6.029 -
TC 107(25.4) 56(24.9) 27(24.8) 0.896 0.976 0.672-1.417 0.981 0.994 0.585-1.687 0.900 0.969 0.596-1.578
TT 312(73.9) 168(74.7) 82(75.2) 0.839 1.039 0.717-1.506 0.912 1.030 0.607-1.748 0.783 1.071 0.658-1.741
TIRAP_975 CC 313(74.2) 153(68.0) 61(56.0) 0.096 0.740 0.519-1.055 0.032 0.598 0.374-0.957 <0.001 0.443 0.286-0.685a
CT 97(23.0) 61(27.1) 40(36.7) 0.245 1.246 0.860-1.806 0.074 1.559 0.957-2.539 0.004 1.942 1.238-3.048
TT 12(2.8) 11(4.9) 8(7.3) 0.181 1.756 0.762-4.046 0.365 1.541 0.601-3.949 0.028 2.706 1.078-6.796
PTB, pulmonary tuberculosis; LTBI, latent tuberculosis infection; HC, healthy control.














Table 3 Distribution of toll-like receptor alleles in the three groups







p OR 95% CI p OR 95% CI p OR 95% CI
TLR1_1805 G 74(8.7) 27(6.0) 12(5.5) 0.077 0.664 0.404-1.064 0.798 0.913 0.412-1.908 0.115 0.606 0.323-1.137
T 770(91.3) 423(94.0) 206(94.5) 0.077 1.506 0.940-2.473 0.798 1.095 0.524-2.425 0.115 1.650 0.880-3.095
rs3804099 C 282(33.4) 145(32.2) 54(24.8) 0.665 0.947 0.736-1.217 0.048 0.693 0.471-1.012 0.014 0.656 0.467-0.921
T 562(66.6) 305(67.8) 164(75.2) 0.665 1.055 0.859-1.244 0.048 1.443 0.988-2.124 0.014 1.524 1.086-2.139
rs5743708 A 840(99.5) 441(98.0) 212(96.8) 0.009 0.233 0.052-0.843 0.538 0.721 0.226-2.500 0.002 0.168 0.047-0.602a
G 4(0.5) 9(2.0) 6(3.2) 0.009 4.291 1.187-19.13 0.538 1.386 0.401-4.429 0.002 5.943 1.662-21.25a
rs3804100 C 252(29.9) 180(40.0) 86(39.4) <0.001 1.566 1.223-2.003a 0.892 0.977 0.692-1.378 0.007 1.531 1.124-2.085
T 592(70.1) 270(60.0) 132(60.0) <0.001 0.638 0.499-0.818a 0.892 1.023 0.742-1.387 0.007 0.653 0.480-0.890
rs1898830 A 480(56.9) 249(55.3) 120(55.0) 0.595 0.939 0.741-1/191 0.944 0.988 0.705-1.387 0.628 0.929 0.688-1.253
G 364(43.1) 201(44.7) 98(45.0) 0.595 1.064 0.840-1.349 0.944 1.012 0.721-1.419 0.628 1.077 0.798-1.453
rs4986790 A 767(90.9) 404(89.8) 185(84.9) 0.521 0.882 0.591-1.325 0.065 0.638 0.385-1.068 0.009 0.563 0.363-0.872
G 77(9.1) 46(10.2) 33(15.1) 0.521 1.133 0.754-1.691 0.065 1.567 0.937-2.595 0.009 1.777 1.146-2.754
rs4986791 C 760(90.0) 401(89.1) 180(82.6) 0.597 1.104 0.690-1.556 0.018 0.579 0.309-0.838a 0.002 0.524 0.345-0.794a
T 84(10.0) 49(10.9) 38(17.4) 0.597 0.905 0.642-1.449 0.018 1.727 1.193-3.235a 0.002 1.910 1.260-2.896a
rs11536889 C 235(27.8) 120(26.7) 60(72.5) 0.651 0.942 0.721-1.228 0.815 1.044 0.712-1.523 0.925 0.984 0.705-1.373
G 609(72.2) 330(73.3) 158(27.5) 0.651 1.061 0.814-1.386 0.815 0.958 0.657-1.404 0.925 1.016 0.728-1.418
rs10759932 C 252(29.9) 132(29.3) 59(27.1) 0.844 0.975 0.752-1.262 0.543 0.894 0.611-1.300 0.419 0.872 0.625-1.216
T 592(70.1) 318(70.7) 159(72.9) 0.844 1.026 0.792-1.330 0.543 1.119 0.769-1.637 0.419 1.147 0.822-1.601
rs7873784 C 193(22.9) 95(21.1) 32(14.7) 0.469 0.903 0.713-1.270 0.047 0.643 0.401-0.912 0.008 1.632 1.084-2.456
G 651(77.1) 355(78.9) 186(85.3) 0.469 1.107 0.787-1.403 0.047 1.555 1.017-2.494 0.008 0.613 0.407-0.923
rs10759931 A 501(59.4) 293(65.1) 142(65.1) 0.043 1.278 0.910-1.488 0.995 1.001 0.704-1.429 0.120 1.164 0.853-10589
G 343(40.6) 157(34.9) 76(34.9) 0.043 0.782 0.672-1.099 0.995 0.999 0.700-1.421 0.120 0.859 0.629-1.173
rs5743810 C 12(1.4) 8(1.8) 5(2.3) 0.621 1.255 0.441-3.366 0.710 1.238 0.330-4.557 0.361 1.628 0.567-4.670
T 832(98.6) 442(98.2) 213(97.7) 0.621 0.197 0.297-2.265 0.710 0.807 0.219-3.034 0.361 0.614 0.214-1.763
TLR_129 C 456(54.0) 258(57.3) 145(66.5) 0.255 1.143 0.774-1.251 0.023 1.478 0.674-1.335 0.001 0.932 0.689-1.261a
G 388(46.0) 192(42.7) 73(33.5) 0.255 0.875 0.799-1.292 0.023 0.676 0.749-1.484 0.001 1.073 0.793-1.451a
rs5743836 C 231(27.4) 151(35.6) 61(28.0) 0.020 1.340 1.038-1.728 0.147 0.769 0.530-1.111 0.857 1.031 0.740-1.437
T 613(72.6) 299(66.4) 157(72.0) 0.020 0.746 0.579-0.964 0.147 1.300 0.900-1.888 0.857 0.970 0.696-1.352
rs1870884 C 113(13.4) 58(12.9) 27(12.4) 0.800 0.957 0.669-1.359 0.855 0.955 0.563-1.591 0.696 0.914 0.584-1.433
T 731(86.6) 392(87.1) 191(87.6) 0.800 1.044 0.736-1.494 0.855 1.047 0.629-1.777 0.696 1.094 0.698-1.713
TIRAP_975 C 723(85.7) 367(81.6) 162(74.3) 0.053 0.740 0.539-1.019 0.031 0.654 0.438-0.983a <0.001 0.484 0.338-0.694a
T 121(14.3) 83(18.4) 56(25.7) 0.053 1.351 0.981-1.855 0.031 1.535 1.017-2.286a <0.001 2.066 1.442-2.960a
PTB, pulmonary tuberculosis; LTBI, latent tuberculosis infection; HC, healthy control.
ap < 0.003125 (0.05/16), the difference was statistically significant after correction for multiple testing (Bonferroni correction).
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culin skin test has a high positive rate in China, but a
positive tuberculin skin test does not conclusively distin-
guish between exposure via contact with Mtb and expos-
ure via BCG vaccination. Therefore, in this study, we used
the TSPOT.TB test to differentiate between LTBI subjects
and individuals who were not infected with Mtb.
We examined 16 markers in seven TLR-related genes
for their association with PTB or LTBI. These six TLRs
were selected because there is strong biological evidenceof their roles in disease susceptibility. We observed sta-
tistically significant associations between TLR2, TLR4,
and TLR9 and susceptibility to PTB or LTBI.
The essential role of TLR2 against mycobacterial infec-
tion has been demonstrated in vivo by the rapid death
[24,25] and higher Mtb burden in TLR2-deficient mice
[25]. Therefore, it is reasonable to suggest that a subtle
reduction in the expression of TLR2 could also make
human more susceptible to the development of TB. In
this study, the genotype and allele distributions of TLR2
Table 4 Haplotypes of the TLR2 and TLR4 genes and their distributions in the three groups
SNP
marker
Haplotype Frequency (No., %) LTBI.vs.HC PTB.vs.LTBI
HC (n = 422) LTBI (n = 225) PTB (n = 109) P OR 95% CI P OR 95% CI
rs3804099 CC 183(21.7) 95(21.1) 52(23.8) 0.812 0.97 0.722-1.289 0.422 1.17 0.779-1.747
rs3804100 CT 185(21.9) 85(18.9) 36(16.5) 0.201 0.83 0.615-1.114 0.455 0.85 0.537-1.326
TC 103(12.2) 56(12.4) 18(8.3) 0.900 1.02 0.709-1.465 0.106 0.63 0.341-1.129
TT 373(44.2) 214(47.6) 112(51.4) 0.247 1.15 0.904-1.450 0.354 1.17 0.832-1.632
rs10759931 AT 376(44.4) 204(45.3) 136(62.4) 0.787 1.03 0.735-1.447 <0.001a 2.00 1.221-3.289
rs10759932 GT 218(25.7) 112(24.9) 22(10.1) 0.712 0.95 0.642-1.401 <0.001a 0.34 0.153-0.694
GC 156(18.5) 88(19.6) 6(2.8) 0.639 1.07 0.693-1.646 <0.001a 0.12 0.022-0.379
AC 94(11.4) 46(10.2) 54(24.7) 0.614 0.91 0.511-1.578 <0.001a 2.89 1.496-5.596
rs4986790 AC 644(76.3) 353(78.4) 157(72.0) 0.383 1.13 0.852-1.505 0.067 0.71 0.481-1.046
rs4986791 AT 49(5.8) 11(2.4) 18(8.3) 0.006 0.39 0.180-0.784 0.001a 3.59 1.570-8.565
GC 33(3.9) 9(2.0) 0(0) 0.065 0.50 0.209-1.083 - - -
GT 118(14.0) 77(17.1) 43(19.7) 0.134 1.27 0.915-1.755 0.409 1.19 0.766-1.833
PTB, pulmonary tuberculosis; LTBI, latent tuberculosis infection; HC, healthy control.
ap < 0.003125 (0.05/16), the difference was statistically significant after correction for multiple testing (Bonferroni correction).
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HC groups, and this may be the first report of an associ-
ation between rs3804100 and LTBI in China. These data
suggest that a defective TLR2 gene is a causative factor
for increased susceptibility to LTBI and its subsequent
progression to PTB disease. Therefore, the detection of
this polymorphism among TB patients may provide im-
portant information in the assessment of their risk pro-
files for susceptibility to TB. We found that the
Arg753Gln (rs5743708) polymorphism was a risk factor
for TB in our Chinese population, which is slightly dif-
ferent from the results of other studies of Vietnamese
patients with TB meningitis [26], Turkish patients with
TB [11,27], and a Croatian Caucasian population [10].
This discrepancy may result from differences in the TB
diagnostic criteria used, the genetics of the populationsFigure 1 LD block structure in TLR2 and TLR4 and in the proximity ofstudied, or differences in sample sizes or analytic ap-
proaches used.
Several investigators have studied the roles of TLR4
genetic polymorphisms in major infectious diseases, in-
cluding TB. In the present study, the rs7873784 poly-
morphism showed a strong association with PTB in our
Chinese population. As reported previously in studies of
Chinese [28], Indonesian [29], and Vietnamese popula-
tions [30], the 299Gly mutation was almost absent in the
present study. However, the AG genotype of rs4986791
was related to PTB disease. This genetic variation in
rs4986791 could alter the extracellular domain of the pro-
tein, which may modulate the interaction of ligands, such
as lipopolysaccharide, with TLR4 [31], leading to an im-
paired immune response and aggravated infection. The
LD observed between the two TLR4 variants (rs4986790the gene in relation to LTBI (left) and PTB (right).
Table 5 MDR analysis of gene–gene and gene–environment interactions in relation to LTBI and PTB
Best model Testing accuracy Testing sensitivity Testing OR Testing χ2 p Cross-validation consistency
PTB.vs.LTBI
BCG 0.61 0.70 1.76(1.067-2.903)a 4.958 0.026a 6/10
rs10759932, rs7873784 0.76 0.72 3.29(2.096-8.283)a 9.253 0.0024a 10/10
rs10759932, rs7873784, rs10759931 0.84 0.81 5.67(3.158-14.99)a 12.67 0.0004a 10/10
LTBI.vs.HC
rs5743836 0.56 0.55 1.68(1.189-2.365)a 8.76 0.0031a 9/10
rs3804100, rs1898830 0.69 0.63 4.57(1.532-13.61)a 7.88 0.005a 10/10
rs3804100, rs1898830, rs10759931 0.80 0.79 5.76(3.332-16.07)a 21.85 0.0001a 10/10
PTB, pulmonary tuberculosis; LTBI, latent tuberculosis infection; HC, healthy control;MDR, multifactor dimensionality reduction.
ap < 0.05.
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relatively weaker than the LD reported among European,
Japanese, and other populations (D’ > 0.9). This discrep-
ancy could result from different environmental and
pathogen-induced selection pressures, causing race-
specific differences in the patterns of evolutionary distri-
bution. The two cosegregating mutations, Thr399Ile and
Asp299Gly, which occur in the ectoplasmic leucine-rich
repeat domain of TLR4, are significantly associated with a
reduced cytokine response to lipopolysaccharide stimula-
tion [32] and increased susceptibility to a variety of infec-
tions [33,34] by affecting the extracellular domain of TLR4
[35]. We also found that SNP rs7873784, in the 3′-un-
translated region (3UTR) of TLR4, was significantly asso-
ciated with PTB in the study population. The effect of the
rs7873784 variant on TB has not been described be-
fore. However, rs7873784 was shown to be associated
with a reduced risk of prostate cancer in an American
population [36]. Together with the results of the
present study, these findings imply that the 3′-UTR
SNP rs7873784 potentially influences the development
of various diseases, making it a good candidate func-
tional SNP.
TLR9 is also known to play an important role in the
activation of the innate immune system. It is the receptor
for viral and bacterial CpG DNA motifs, and several stud-
ies have shown that the binding of TLR9 is necessary to
drive the Th1 immune response [37,38]. In the present
study, the TLR9 polymorphism rs5743836 was associated
with the risk of LTBI. This polymorphism in TLR9 has
been consistently associated with increased transcriptional
activity [39,40], supporting the notion that rs5743836 en-
hances TLR9 function and increases susceptibility to LTBI.
TIRAP has two isoforms, both of which have a C-
terminal TIR domain that mediates signals from TLR2
and TLR4. However, in the present study, no associ-
ation was observed between the TIRAP polymorphism
(975C/T) Ser180Leu and PTB or LTBI.
Because TLR6 mediates the recognition of lipopeptides
when it forms a heterodimer with TLR2, we also examinedthe TLR6 745C/T (rs5743810) polymorphism and ob-
served a lower frequency of the C allele in the PTB and
LTBI groups than in the HC group. However, the fre-
quency was too low for a proper statistical evaluation, so
the possible association between this TLR6 polymorphism
and human susceptibility to TB disease is yet to be con-
firmed in a Chinese population.
Several loci usually contribute to the phenotypes
expressed in complex diseases, including TB. Therefore,
it is important to identify gene–gene interactions (epista-
sis), because they may more accurately predict the risk
of disease than single genes. In the present study, an
MDR analysis was used to predict potential gene–gene
and gene–environment interactions that may partly
determine the complex phenotypes produced by Mtb
pathogenesis. We found that rs3804100, rs1898830,
and rs10759931 were associated with LTBI, whereas
rs10759932, rs7873784, and rs10759931 were associated
with PTB. These findings are consistent with the recently
identified links between TLRs and the innate immune re-
sponse to Mtb, i.e., the relationship between TLR signal-
ing, the upregulated expression of the vitamin D receptor,
and the vitamin-D-mediated killing of intracellular Mtb by
the antimicrobial peptide cathelicidin [41]. However, these
SNPs cannot be used to interpret the immunological find-
ings that pertain to LTBI and subsequent PTB. Nonethe-
less, as noted above, they suggest that different cytokine
pathways are important in LTBI and PTB. Further studies
are required to determine whether these polymorphisms
can account for this epidemiological finding.
The strength of this study was the differentiation of
LTBI cases from HCs, which provided an opportunity to
analyze the impact of TLR polymorphisms on the suscep-
tibility to both LTBI and PTB. However, this study had
some limitations. The individuals in the three groups were
not matched for other risk factors (e.g., BCG vaccination),
so their susceptibility to PTB and LTBI may have resulted
not only from genetic factors. However, gene–gene and
gene–environment interactions were evaluated in relation
to LTBI and PTB. Furthermore, a few SNPs identified in
Wu et al. BMC Medical Genetics  (2015) 16:19 Page 10 of 11the LTBI and PTB groups deviated slightly from Hardy–
Weinberg equilibrium in the HC group. However, these
deviations were not significant (p > 0.01) and did not sug-
gest significant genotyping errors. The observed devia-
tions from Hardy–Weinberg equilibrium in the TLR
polymorphisms in this Chinese population may indicate a
functional effect, suggesting that more power may be ne-
cessary to observe such associations in China. We ac-
knowledge that an important limitation of our study is the
small sample size, which may also have a significant im-
pact on observed statistical significance. This is the case of
SNP rs5743708, where homozygotes for the minor allele
were not detected and minimal heterozygotes’ frequency
fluctuations would obliterate the positive association re-
sult. Replication by independent studies with adequately
powered sample size, will be necessary to confirm or re-
fute our findings.Conclusion
Taken together, our results suggest that polymorphisms
in TLR2 influence the risk of LTBI and subsequent PTB
in the Chinese population, and that variations in TLR4
and TLR9 influence the risk of LTBI and PTB disease,
respectively. Clarification of the precise roles that these
genes play in TB susceptibility will require the isolation
of functional variants of TLR2, TLR4, and TLR9 that can
explain these variations. Epidemiological studies and
basic and genetic research will extend our understanding
of the critical determinants of host susceptibility to Mtb
in different populations, and may provide new insights
into the effects of genetic heterogeneity on the develop-
ment of the different stages of TB.Additional file
Additional file 1: Table S1. Primer sequences and restriction enzymes
used for genotyping the studied TLR genes.Abbreviations
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